Menu
Search
|

Menu

Close
X

Beigene Ltd BGNE.OQ (NASDAQ Stock Exchange Global Select Market)

127.02 USD
+0.02 (+0.02%)
As of Nov 16
chart
Previous Close 127.00
Open 127.28
Volume 351,484
3m Avg Volume 120,083
Today’s High 128.65
Today’s Low 125.28
52 Week High 220.09
52 Week Low 77.60
Shares Outstanding (mil) 63.88
Market Capitalization (mil) 13,511.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
140
FY17
238
FY16
1
FY15
9
EPS (USD)
FY18
-0.575
FY17
-0.183
FY16
-0.274
FY15
-0.139
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
85.67
20.58
Price to Book (MRQ)
vs sector
3.45
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
9.95
13.84
LT Debt to Equity (MRQ)
vs sector
9.50
9.93
Return on Investment (TTM)
vs sector
-32.11
13.58
Return on Equity (TTM)
vs sector
-36.92
15.11

EXECUTIVE LEADERSHIP

John Oyler
Chairman of the Board, Chief Executive Officer, Founder, Since 2010
Salary: $97,664.00
Bonus: $1,272,070.00
Xiaobin Wu
President, Since 2018
Salary: --
Bonus: --
Howard Liang
Chief Financial Officer and Chief Strategy Officer, Since 2015
Salary: --
Bonus: --
Wendy Yan
Senior Vice President, Head of Regulatory Affairs, Since 2014
Salary: $68,510.00
Bonus: --
Jason Yang
Senior Vice President, Head of Clinical Development, Since 2014
Salary: $116,129.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

C/O Mourant Ozannes Corporate Se
94 Solaris Avenue, Camana Bay
BEIJING   BEJ   KY1-1108

Phone: +1345.9494123
Site:

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

SPONSORED STORIES